Introducing EMJ Diabetes 4.1 - European Medical Journal

Introducing EMJ Diabetes 4.1

United Kingdom, October 27, 2016: Welcome to the newest edition of EMJ Diabetes, filled with interviews, abstracts, peer-reviewed papers, and the most recent developments related to the study and treatment of diabetes. While autumn is well underway, congress events and symposia are still aplenty. This issue covers highlights and updates from the European Association for the Study of Diabetes (EASD) 2016 Congress, as well as interviews with a selection of EMJ’s internationally renowned Editorial Board.

This year, the EASD Congress took place in Munich, Germany, with 1,167 abstracts presented as both poster sessions and short discussions. A new addition this year was the introduction of evening seminars to supplement the industry symposia. These evening sessions allowed even more opportunities for companies to showcase innovations and products from the forefront of diabetes research. Inside, a comprehensive report on the EASD Congress is included, featuring the latest news stories from the event and providing updates on the vast volume of innovative study that is being carried out across Europe and the world. Complementing this, there are a number of abstract reviews, summarised by their respective authors from their presentations at EASD. These span from the review of a novel practical screening tool for detecting silent myocardial infarction with Type 2 diabetes mellitus (T2DM), to the potential of using C-reactive protein levels as a biomarker for cardiovascular risk in metabolically-healthy obesity.

Furthermore, this year’s eJournal presents a selection of high-quality peer-reviewed articles spanning the field of diabetes to guide the future practice of clinicians worldwide. Rizvi reviews the treatment of T2DM with biphasic insulin analogues, while similarly, the potential of novel therapeutics for T2DM and its associated adverse effects on the skeleton are assessed by Berberoglu in this edition’s Editor’s pick. Additionally, Tollo et al. describe the promising anti-hyperglycaemic, anti-hyperlipidaemic, and lipid profile regulatory properties of Moringa oleifera leaf powder in early T2DM diagnosis patients; Rajput and Jain review the present role and future use of HbA1c level monitoring in the diagnosis of gestational diabetes mellitus; and Stewart discusses individualised treatment strategies for chorioretinal vascular diseases.

The content of this publication should provide those with interest in the field of diabetes with valuable insights to guide future research and clinical practice. Zoë Webster, Head of Publishing at EMJ emphasised: “We feel that this issue of EMJ Diabetes has captured the most innovative progresses within the field and hope that the novel clinical approaches introduced will provoke much discussion and debate.”


About the European Medical Journal
The European Medical Journal is an independent company that annually produces a collection of open-access medical eJournals covering therapeutic areas such as Respiratory, Gastroenterology, Cardiology, and Urology. By combining editorials from key opinion leaders with concise news coverage from the leading congresses within the medical industry, we aim to deliver first-class insight into ground-breaking changes and advances in medicine. The production of our high-quality, peer-reviewed eJournals, and our collaborations with independent clinical bodies result in a dynamic and contemporary tool with which to assist industry professionals across Europe in progressively developing their performance and efficacy.

Media Contact
Name: Stacey Rivers
Number: 01245 334452
E-mail: [email protected]

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?